PE20221661A1 - Anticuerpos anti-ccl2 biespecificos - Google Patents

Anticuerpos anti-ccl2 biespecificos

Info

Publication number
PE20221661A1
PE20221661A1 PE2022001097A PE2022001097A PE20221661A1 PE 20221661 A1 PE20221661 A1 PE 20221661A1 PE 2022001097 A PE2022001097 A PE 2022001097A PE 2022001097 A PE2022001097 A PE 2022001097A PE 20221661 A1 PE20221661 A1 PE 20221661A1
Authority
PE
Peru
Prior art keywords
cdr
seq
domain
bispecific anti
ccl2
Prior art date
Application number
PE2022001097A
Other languages
English (en)
Inventor
Shu Feng
Jens Fischer
Siok Wan Gan
Guy Georges
Michael Gertz
Wei Shiong Adrian Ho
Anton Jochner
Gregor Jordan
Hubert Kettenberger
Runyi Adeline Lam
Meher Majety
Joerg Moelleken
Valeria Runza
Martin Schaefer
Tilman Schlothauer
Georg Tiefenthaler
Maria Viert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20221661A1 publication Critical patent/PE20221661A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Abstract

SE REFIERE A ANTICUERPOS ANTI-CCL2 BIESPECIFICOS QUE SE UNEN A DOS EPITOPOS DIFERENTES EN EL CCL2 HUMANO QUE COMPRENDE UN PRIMER SITIO DE UNION A ANTIGENO QUE COMPRENDE UN DOMINIO VH QUE COMPRENDE UNA CDR-H1 DE SEQ ID NO: 33, UNA CDR-H2 DE SEQ ID NO: 34, UNA CDR-H3 DE SEQ ID NO: 35, Y UN DOMINIO VL QUE COMPRENDE UNA CDR-L1 DE SEQ ID NO: 36, UNA CDR-L2 DE SEQ ID NO: 37 Y UNA CDR-L3 DE SEQ ID NO: 38; Y UN SEGUNDO SITIO DE UNION A ANTIGENO COMPRENDE UN DOMINIO VH QUE COMPRENDE UNA CDR-H1 DE SEQ ID NO: 41, UNA CDR-H2 DE SEQ ID NO: 42, UNA CDR-H3 DE SEQ ID NO: 43, Y UN DOMINIO VL QUE COMPRENDE UNA CDR-L1 DE SEQ ID NO: 44, UNA CDR-L2 DE SEQ ID NO: 45 Y UNA CDR-L3 DE SEQ ID NO: 46. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE UTIL EN EL TRATAMIENTO DE CANCER.
PE2022001097A 2019-12-18 2020-12-16 Anticuerpos anti-ccl2 biespecificos PE20221661A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19217665 2019-12-18
PCT/EP2020/086403 WO2021122733A1 (en) 2019-12-18 2020-12-16 Bispecific anti-ccl2 antibodies

Publications (1)

Publication Number Publication Date
PE20221661A1 true PE20221661A1 (es) 2022-10-26

Family

ID=69024103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001097A PE20221661A1 (es) 2019-12-18 2020-12-16 Anticuerpos anti-ccl2 biespecificos

Country Status (18)

Country Link
US (3) US11739142B2 (es)
EP (1) EP4076663A1 (es)
JP (2) JP7415005B2 (es)
KR (1) KR20220113791A (es)
CN (1) CN114867532A (es)
AR (1) AR120795A1 (es)
AU (1) AU2020403913A1 (es)
BR (1) BR112022012010A2 (es)
CA (1) CA3164818A1 (es)
CL (1) CL2022001677A1 (es)
CO (1) CO2022009205A2 (es)
CR (1) CR20220277A (es)
IL (1) IL293310A (es)
MX (1) MX2022007479A (es)
PE (1) PE20221661A1 (es)
TW (1) TW202136299A (es)
WO (1) WO2021122733A1 (es)
ZA (1) ZA202206008B (es)

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
PT1562972E (pt) 2002-10-15 2010-11-10 Facet Biotech Corp Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese
AU2003293096B9 (en) 2002-11-27 2011-09-29 Biogen Ma Inc. Humanized antibodies against monocyte chemotactic proteins
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1812068A4 (en) 2004-10-29 2010-06-09 Medimmune Inc METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ATE425186T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
DK2383297T5 (da) 2006-08-14 2022-07-04 Xencor Inc Optimerede antistoffer rettet mod CD19
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US8906680B2 (en) 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
CN101827610A (zh) 2007-06-29 2010-09-08 森托科尔奥索生物科技公司 抗mcp-1抗体、组合物、方法和用途
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2808343T1 (sl) 2007-12-26 2019-10-30 Xencor Inc Fc-variante s spremenjeno vezavo na FcRn
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
KR20190025057A (ko) 2008-10-14 2019-03-08 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
CA2829131C (en) 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
SI2748202T1 (sl) 2011-08-23 2018-10-30 Roche Glycart Ag Bispecifične molekule, ki se vežejo na antigen
AU2012313594C1 (en) 2011-09-30 2018-05-10 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047752A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 抗原の消失を促進する抗原結合分子
WO2013081143A1 (ja) 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
JP6138108B2 (ja) 2012-02-24 2017-05-31 中外製薬株式会社 ＦｃγＲＩＩＢを介して抗原の消失を促進する抗原結合分子
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
DK2857420T3 (da) 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd Målvævsspecifikt antigenbindende molekyle
US20150353630A1 (en) 2012-05-30 2015-12-10 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP2970508A4 (en) 2013-03-15 2016-12-14 Permeon Biologics Inc GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
BR112015029300A2 (pt) * 2013-05-23 2017-09-19 Shire Human Genetic Therapies Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN106573986A (zh) 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
PE20221834A1 (es) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CN107787332B (zh) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
CR20180217A (es) 2015-09-18 2018-05-03 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
EP3621641A4 (en) * 2017-05-08 2021-03-03 Adimab, LLC ANTI-CD3 BINDING DOMAINS AND ANTIBODIES CONTAINING THEM AND THE METHOD OF MANUFACTURING AND USING THEM

Also Published As

Publication number Publication date
KR20220113791A (ko) 2022-08-16
EP4076663A1 (en) 2022-10-26
ZA202206008B (en) 2023-03-29
CL2022001677A1 (es) 2023-02-03
CN114867532A (zh) 2022-08-05
CR20220277A (es) 2022-08-31
US20240117029A1 (en) 2024-04-11
AU2020403913A1 (en) 2022-06-09
US11739142B2 (en) 2023-08-29
BR112022012010A2 (pt) 2022-08-30
JP2023506811A (ja) 2023-02-20
JP7415005B2 (ja) 2024-01-16
CO2022009205A2 (es) 2022-07-08
WO2021122733A1 (en) 2021-06-24
CA3164818A1 (en) 2021-06-24
JP2024050565A (ja) 2024-04-10
AR120795A1 (es) 2022-03-16
US20210188960A1 (en) 2021-06-24
IL293310A (en) 2022-07-01
US20240083993A1 (en) 2024-03-14
TW202136299A (zh) 2021-10-01
MX2022007479A (es) 2022-06-29

Similar Documents

Publication Publication Date Title
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
PE20091474A1 (es) Anticuerpos monoclonales contra la proteina rgm a y sus usos
PE20141186A1 (es) Proteinas de union al tnf-alfa
IL299221A (en) CD3 binding antibodies
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
JP2017534577A5 (es)
JP2017536341A5 (es)
JP2016510002A5 (es)
PE20141564A1 (es) Moleculas de union para bcma y cd3
JP2018507220A5 (es)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2020037555A5 (es)
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
HRP20190917T1 (hr) NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE
JP2016538318A5 (es)
RU2011116112A (ru) Биспецифические анти-egfr/анти-igf-1r антитела
NZ596136A (en) Anti-cd100 antibodies and methods for using the same
RS53405B (en) CXCR4 HUMANIZED ANTIBODIES FOR CANCER TREATMENT
HRP20202047T1 (hr) Antitijelo za igf-1r i njegova upotreba kao usmjeravajućeg vezikula za liječenje karcinoma
PE20221869A1 (es) Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap
JP2016527225A5 (es)